Thus, the designed HTNV MAP may have a stronger capacity to induce the proliferation of CD8+ T cells than the single HTNV CTL epitope in patients with HLA-A*02+ HFRS. This evidence concerns the gene HLA-A and hemorrhagic fever with renal syndrome.